2-azetidinone cholesterol absorption inhibitors: Structure-activity relationships on the heterocyclic nucleus

被引:119
|
作者
Clader, JW
Burnett, DA
Caplen, MA
Domalski, MS
Dugar, S
Vaccaro, W
Sher, R
Browne, ME
Zhao, HR
Burrier, RE
Salisbury, B
Davis, HR
机构
[1] Schering-Plough Research Institute, Kenilworth, NJ 07033-0539
关键词
D O I
10.1021/jm960405n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of azetidinone cholesterol absorption inhibitors related to SCH 48461 ((-)-6) has been prepared, and compounds were evaluated for their ability to inhibit hepatic cholesteryl ester formation in a cholesterol-fed hamster model. Although originally designed as acyl CoA: cholesterol acyltransferase (ACAT) inhibitors, comparison of in vivo potency with in vitro activity in a microsomal ACAT assay indicates no correlation between activity in these two models. The molecular mechanism by which these compounds inhibit cholesterol absorption is unknown. Despite this limitation, examination of the in vivo activity of a range of compounds has revealed clear structure-activity relationships consistent with a well-defined molecular target. The details of these structure-activity relationships and their implications on the nature of the putative pharmacophore are discussed.
引用
收藏
页码:3684 / 3693
页数:10
相关论文
共 50 条
  • [31] Synthesis, antimicrobial and cytotoxic activity of 2-azetidinone derivatives of pyridyl benzimidazoles
    N. C. Desai
    D. D. Pandya
    G. M. Kotadiya
    Priyanka Desai
    Medicinal Chemistry Research, 2014, 23 : 1725 - 1741
  • [32] Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors
    Yuan, Xinrui
    Lu, Peng
    Xue, Xiaojian
    Qin, Hui
    Fan, Chen
    Wang, Yubin
    Zhang, Qi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) : 849 - 853
  • [33] Structure-activity relationships for synthetic peptide inhibitors of thrombin
    Clement, CC
    Gingold, J
    Philipp, M
    FASEB JOURNAL, 2003, 17 (05): : A1006 - A1006
  • [34] Structure-activity relationships of selective GABA uptake inhibitors
    Hog, Signe
    Greenwood, Jeremy R.
    Madsen, Karsten B.
    Larsson, Orla M.
    Frolund, Bente
    Schousboe, Arne
    Krogsgaard-Larsen, Povl
    Clausen, Rasmus P.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (17) : 1861 - 1882
  • [35] An Overview of Thrombin Inhibitors in the Perspective of Structure-activity Relationships
    Wang, Jiangming
    Sun, Xiaojing
    Li, Na
    Sheng, Ruilong
    Guo, Ruihua
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (25) : 2864 - 2930
  • [36] Inhibitors of vitamin D hydroxylases: Structure-activity relationships
    Schuster, I
    Egger, H
    Nussbaumer, P
    Kroemer, RT
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) : 372 - 380
  • [37] Structure-activity relationships of carbocyclic influenza neuraminidase inhibitors
    Williams, MA
    Lew, W
    Mendel, DB
    Tai, CY
    Escarpe, PA
    Laver, WG
    Stevens, RC
    Kim, CU
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (14) : 1837 - 1842
  • [38] Structure-activity relationships of novel potent MurF inhibitors
    Gu, YG
    Florjancic, AS
    Clark, RF
    Zhang, TY
    Cooper, CS
    Anderson, DD
    Lerner, CG
    McCall, JO
    Cai, YN
    Black-Schaefer, CL
    Stamper, GF
    Hajduk, PJ
    Beutel, BA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) : 267 - 270
  • [39] The development of novel telomerase inhibitors: Structure-activity relationships
    Cheng, MK
    Modi, C
    Grindon, CR
    Stevens, MFG
    Laughton, CA
    BRITISH JOURNAL OF CANCER, 2003, 88 : S40 - S40
  • [40] Structure-activity relationships of PDE5 inhibitors
    Eros, D.
    Szantai-Kis, Cs.
    Kiss, R.
    Keri, Gy.
    Hegymegi-Barakonyi, B.
    Koevesdi, I.
    Orfi, L.
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (16) : 1570 - 1585